To the editor:

We read with great interest the paper published in Journal of Hepatology by Iavarone et al., \[[@bib1]\], which is very important for our daily practice as hepatologists, particularly in Egypt; the country with the highest prevalence of HCV in the world and the current peak for COVID-19 reported cases \[[@bib2]\]. The authors concluded that COVID-19 infection is associated with higher 30-day mortality rates in cirrhotic patients; however, we are not sure about rationality of the generalization of this conclusion.

We think that the sample size is too small to evaluate the actual effect of COVID-19 infection on the mortality rates in cirrhotic patients. Additionally, old age was assigned to be the most important prognostic factor for mortality in COVID-19 patients since the onset of the pandemic. The median age of the study population is 67 years old (IQR 61-74), which is significantly older than the comparative group of cirrhotic patients with pneumonia (59, IQR 50-65), which may affect the mortality rate in the former group. A recently published meta-analysis showed that the mortality rate in COVID-19 patients at the age groups 50-59, 60-69, 70-79, to be 3%, 9.5%, and 22.5%, respectively \[[@bib3]\], and the median age of the dead patients was 70 (IQR 61-80). Moreover, 48% of the included patients had decompensated cirrhosis at the time of their last outpatient visit, which carries a 1-year probability of mortality of about 20% \[[@bib4]\], even in the absence of COVID-19 infection.

Multiple co-morbidities were reported in the study group other than liver cirrhosis; so, high rates of mortality can't be attributed to complications of liver cirrhosis alone. As regards the group of cirrhotic patients with pneumonia, the number of patients with co-morbidities was lower in this group relative to cirrhotic patients with COVID-19 infection, which may play a role in lower mortality rate in patients without COVID-19.

The majority of deaths (12 out of 17) were due to respiratory failure, while only five were due to end-stage liver disease, which may indicate a modest effect of COVID-19 infection on mortality among cirrhotic patients. Furthermore, the authors did not document the occurrence of hepatopulmonary syndrome and/or porto-pulmonary hypertension in the recruited patient, which could affect the respiratory failure rate in this study. Among the reported co-morbidities in the study, was the chronic obstructive pulmonary disease (COPD), and it would be of great importance to clarify its relationship to the occurrence of respiratory failure in patients with Acute-on-Chronic Liver Failure (ACLF).

What was really interesting is that nosocomial SARS-CoV-2 infection was documented in 40% of the study patients, which emphasize the importance of EASL \[[@bib5]\] and AASLD \[[@bib6]\] recommendations regarding the role of telemedicine in the management of cirrhotic patients during COVID-19 pandemic, and the advice to postpone any in-hospital procedures for those patients whenever possible.

Finally, we thank Dr. Iavarone et al. for their important thoughts on the risks that face cirrhotic patients during COVID-19 era, which pave the way for further studies to better evaluate this important issue. What\'s more, and with different observational studies merged into larger databases from various geographical areas, the issue of encountering peculiar impact of COVID-19 on chronic liver disease patients may be much easier to ascertain.
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